Posted by Michael Wonder on 25 Jul 2025
FDA grants priority review for Addyi (flibanserin) paving the way for expanded access to treat low sexual desire in post-menopausal women
24 July 2025 - Sprout Pharmaceuticals today announced that the US FDA has granted priority review for its supplemental application to expand the indication of Addyi (flibanserin 100 mg), the first and only FDA approved pill for low sexual desire in women, to also include women who have gone through menopause.
This marks a potential pivotal advancement in women's sexual health, addressing a long-standing unmet need for millions of women experiencing hypoactive sexual desire disorder.
